Here are the 10-K annual reports from Sangamo Therapeutics Inc (SGMO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SGMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMO filings page.
Sangamo Therapeutics filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership and governance without changing previously reported financial results. The amendment also refreshes officer certifications.
The filing outlines a 2025 executive pay program where CEO Alexander Macrae’s total compensation was about $2.6 million, including equity awards and a cash bonus earned under a plan that reached 40% of corporate goals. All 2025 bonuses and approved 2025 salary increases for named executives remain deferred until the company raises additional funding, and Macrae voluntarily waived his 2025 bonus.
Board and committee retainers, director equity grants, and extensive outstanding stock option and RSU positions are described, along with major 2025 and early 2026 equity financings that raised roughly $21.1 million and $23.1 million. As of April 20, 2026, Sangamo had 414,275,509 shares outstanding, with Armistice Capital and Yorkville each holding more than 10% of the common stock, subject to warrant-related beneficial ownership limits.
Sangamo Therapeutics’ annual report highlights both scientific progress and severe financial strain. The company focuses on zinc finger–based genomic medicines for neurologic diseases, including ST-503 for chronic neuropathic pain and ST-506 for prion disease, plus a strong AAV capsid platform (STAC-BBB) licensed to major partners.
Sangamo reports positive Phase 1/2 data for its Fabry gene therapy isaralgagene civaparvovec, including favorable kidney function slopes and quality-of-life gains, and has begun a rolling BLA submission under the FDA’s Accelerated Approval pathway. However, management states there is substantial doubt about its ability to continue as a going concern, warning it needs substantial near-term funding and may have to cease operations or seek U.S. bankruptcy protection.
The company has received significant collaboration revenue and could earn large future milestones, but also notes ongoing Nasdaq listing noncompliance, potential delisting, high dilution risk, and continued operating losses with no approved products.